Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice

Pharmacology Biochemistry and Behavior

Volumn 77, Issue 2, 2004, Pages 309-318

  Cook, Charles D ^a   Newman, Jennifer L ^a   Winfree, Jennifer C ^a   Beardsley, Patrick M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

BP897; D2 3 agonist; D2 3 antagonist; Locomotor; Mice; MK801; Nafadotride; Psychomotor

Indexed keywords

BP 897; DIZOCILPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; ETICLOPRIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NAFADOTRIDE; QUINELORANE; QUINPIROLE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; LOCOMOTION; MALE; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; TRAVEL;

EID: 1642534423     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2003.11.002     Document Type: Article

References (44)

1. Aretha C.W., Sinha A., Galloway M.P. Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. J. Pharmacol. Exp. Ther. 274:1995;609-613.
2. Audinot V., Newman-Tancredi A., Gobert A., Rivet J.M., Brocco M., Lejeune F.et al. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J. Pharmacol. Exp. Ther. 287:1998;187-197.
3. Boulay D., Depoortere R., Perrault G., Borrelli E., Sanger D.J. Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists. Neuropharmacology. 38:1999;1389-1396.
4. Boulay D., Depoortere R., Rostene W., Perrault G., Sanger D.J. Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology. 38:1999;555-565.
5. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropharmacology. 1:1988.
6. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural. Transm. 75:1989;221-226.
7. Chausmer A.L., Katz J.L. The role of D2-like dopamine receptors in the locomotor stimulant effects of cocaine in mice. Psychopharmacology. 155:2001;69-77.
8. Chio C.L., Lajiness M.E., Huff R.M. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol. 45:1994;51-60.
9. Cook C.D., Beardsley P.M. The modulatory actions of dopamine D2/3 agonists and antagonists on the locomotor-activating effects of morphine and caffeine in mice. Pharmacol. Biochem. Behav. 75:2003;363-371.
10. Cook C.D., Rodefer J.S., Picker M.J. Selective attenuation of the antinociceptive effects of mu opioid by the putative dopamine D3 agonist 7-OH-DPAT. Psychopharmacology. 144:1999;239-247.
11. Cook C.D., Barrett A.C., Syvanthong C., Picker M.J. Modulatory effects of dopamine D3/2 agonists on kappa opioid-induced antinociception and diuresis in the rat. Psychopharmacology. 152:2000;14-23.
12. Dekeyne A., Rivet J.M., Gobert A., Millan M.J. Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128, 907 and 7-OH-DPAT. Neuropharmacology. 40:2001;899-910.
13. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol. 393:2000;295-314.
14. Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244:1988;1067-1080.
15. Di Chiara G., Acquas E., Tanda G. Ethanol as a neurochemical surrogate of conventional reinforcers: the dopamine-opioid link. Alcohol. 13:1996;13-17.
16. Gainetdinov R.R., Sotnikova T.D., Grekhova T.V., Rayevsky K.S. In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur. J. Pharmacol. 308:1996;261-269.
17. Gilbert D.B., Millar J., Cooper S.J. The putative dopamine D3 agonist, 7-OH-DPAT, reduces dopamine release in the nucleus accumbens and electrical self-stimulation to the ventral tegmentum. Brain Res. 681:1995;1-7.
18. Gobert A., Rivet J.M., Audinot V., Cistarelli L., Spedding M., Vian J.et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J. Pharmacol. Exp. Ther. 275:1995;899-913.
19. Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm. Gen. Sect. 89:1992;1-10.
20. Irifune M., Shimuzu T., Nomoto M., Fukuda T. Involvement of N-methyl-D-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice. Pharmacol. Biochem. Behav. 51:1995;291-296.
21. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
22. Koeltzow T.E., Xu M., Cooper D.C., Hu X.-T., Tonegawa S., Wolf M.E.et al. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J. Neurosci. 18:1998;2231-2238.
23. Leriche L., Schwartz J.C., Sokoloff P. The dopamine D(3) receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology. 45:2003;174-181.
24. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 49:1997;231-252.
25. Levant B., Vansell N.R. In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology. 17:1997;67-71.
26. Lodge D., Johnson K.M. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol. Sci. 11:1990;81-86.
27. Marcus M.M., Mathe J.M., Nomikos G.G., Svensson T.H. Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens. Neuropharmacology. 40:2001;482-490.
28. Marino M.J., Conn P.J. Direct and indirect modulation of the N-methyl-D-aspartate receptor. Curr. Drug Target CNS Neurol. Disord. 1:2002;1-16.
29. Narayanan S., Willins D., Dalia A., Wallace L., Uretsky N. Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol. Biochem. Behav. 54:1996;565-573.
30. Navarro M., Fernandez-Ruiz J.J., de Miguel R., Hernandez M.L., Cebeira M., Ramos J.A. An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Behav. Brain. Res. 57:1993;37-46.
31. Ouagazzal A., Nieoullon A., Amalric M. Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacology. 111:1993;427-434.
32. Pilla M., Perachon S., Sautel F., Garrido F., Mann A., Wermuth C.G.et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature. 400:1999;371-375.
33. Rao T.S., Kim H.S., Lehmann J., Martin L.L., Wood P.L. Interactions of phencyclidine receptor agonist MK-801 with dopaminergic system: regional studies in the rat. J. Neurochem. 54:1990;1157-1162.
34. Sautel F., Griffon N., Levesque D., Pilon C., Schwartz J.C., Sokoloff P. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport. 6:1995;329-332.
35. Sautel F., Griffon N., Sokoloff P., Schwartz J.C., Launay C., Simon P.et al. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 275:1995;1239-1246.
36. Schwartz J.C., Diaz J., Pilon C., Sokoloff P. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Rev. 31:2000;277-287.
37. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophreniafs. Synapse. 1:1987;133-152.
38. Sotnikova T.D., Gainetdinov R.R., Grekhova T.V., Rayevsky K.S. Effects of intrastriatal infusion of D2 and D3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum (in vivo microdialysis study). Pharmacol. Res. 43:2001;283-290.
39. Starr M.S., Starr B.S. Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice. Psychopharmacology. 114:1994;469-476.
40. Suzuki T., Kato H., Aoki T., Tsuda M., Narita M., Misawa M. Effects of the non-competitive NMDA receptor antagonist ketamine on morphine-induced place preference in mice. Life Sci. 67:2000;383-389.
41. Verma A., Kulkarni S.K. Modulation of MK-801 response by dopaminergic agents in mice. Psychopharmacology. 107:1992;431-436.
42. Wicke K., Garcia-Ladona J. The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. Eur. J. Pharmacol. 424:2001;85-90.
43. Witkin J., Gasior M., Acri J., Beekman M., Thurkauf A., Yuan J. Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907. Eur. J. Pharmacol. 347:1998;R1-R3.
44. Wood M.D., Boyfield I., Nash D.J., Jewitt F.R., Avenell K.Y., Riley G.J. Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. Eur. J. Pharmacol. 407:2000;47-51.